Misfolded proteins of the secretory pathway are extracted from the endoplasmic reticulum (ER), polyubiquitylated by a protein complex termed the Hmg-CoA reductase degradation ligase (HRD ligase) and degraded by cytosolic 26S proteasomes. The movement of these proteins through the lipid bilayer is assumed to occur via a protein-conducting channel of unknown nature. We show that the integral membrane protein Der1 oligomerizes, which relies on its interaction with the scaffolding protein Usa1. Mutations in the transmembrane domains of Der1 block the passage of soluble proteins across the ER membrane. As determined by site-specific photocrosslinking, the ER-luminal exposed parts of Der1 are in spatial proximity to the substrate receptor Hrd3, whereas the membrane-embedded domains reside adjacent to the ubiquitin ligase Hrd1. Intriguingly, both regions also form crosslinks to client proteins. Our data imply that Der1 initiates the export of aberrant polypeptides from the ER lumen by threading such molecules into the ER membrane and routing them to Hrd1 for ubiquitylation.
Folding of newly synthesized proteins in the secretory pathway is monitored by a quality control system that routes terminally aberrant polypeptides from the ER into the cytosol where they are polyubiquitylated and degraded by proteasomes. This process, termed ER-associated protein degradation 1,2 (ERAD), is pivotal for the maintenance of cellular homeostasis and its mechanistic exploration will contribute to the treatment of various neurodegenerative disorders [3] [4] [5] and folding diseases such as cystic fibrosis 6, 7 . Key components of ERAD are large multi-subunit ubiquitin ligases, which are embedded in the ER membrane 8 . In yeast, the HRD ligase promotes the degradation of soluble ER-luminal as well as membrane-bound substrates. The core of this complex encompasses the RING-finger type ubiquitin ligase Hrd1, which is integrated in the ER membrane and exposes its catalytically active centre to the cytoplasm 9, 10 . Hrd1 teams up with the substrate receptors Hrd3 and Yos9, which expose large soluble domains into the ER lumen, and Usa1, which facilitates the assembly of the ligase complex [11] [12] [13] [14] [15] . Intriguingly, another subunit Der1, an integral membrane protein with several transmembrane segments that is recruited to Hrd1 through Usa1, is required only for the turnover of soluble but dispensable for the degradation of membrane-bound substrates [16] [17] [18] [19] . As Der1 weakly binds client proteins, it has been speculated that it either resembles a receptor for soluble targets or partakes in the dislocation of such polypeptides from the ER (refs 12,20) . How aberrant proteins are exported from the ER in the course of ERAD is unknown. Remarkably, fully glycosylated and even partially folded ERAD substrates have been shown to traverse the ER membrane before their degradation 21 . This transport relies on the activity of the ubiquitin ligases and is generally believed to involve a proteinaceous channel [22] [23] [24] . Several candidates for the constitution of such a dislocation apparatus have been discussed 25, 26 . Here we report that the transmembrane domains of Der1 constitute a functional entity that is important for ERAD. Furthermore, soluble and membrane-embedded parts of Der1 are in spatial proximity to other components of the HRD ligase and to dislocating substrate molecules. Our data imply that Der1 establishes a functional link between the selection of aberrant proteins in the ER lumen and their ubiquitylation in the cytoplasm by promoting the insertion of such polypeptides into the ER membrane.
RESULTS

Usa1-dependent integration of Der1 into the HRD ligase promotes oligomerization
To assess possible functions of Der1 we were first interested in how this protein is integrated into the HRD ligase protein complex. Usa1 links Der1 to Hrd1, which renders the ligase competent for the proteolysis of misfolded luminal ER proteins 14, 27 . Sequence alignment of Der1 and its mammalian homologues, the derlins, revealed an arrangement of conserved residues in the carboxy-terminal region (Gly 179/His 180 and Tyr 183/184; Supplementary Fig. 1a ). The mutation of these residues specifically reduced the association with Usa1 as determined by co-immunoprecipitation experiments with Usa1-Myc ( Fig. 1a and Supplementary Table 1) . Besides its linker function, Usa1 also conveys the stability of Der1 (ref. 14). Indeed, Der1 was degraded in a Hrd1-and Doa10-dependent manner in cells lacking Usa1 ( Supplementary  Fig. 1b) . Accordingly, the Usa1-binding-deficient Der1 mutants were unstable ( Supplementary Fig. 1c ).
Der1 and other components of the HRD ligase have been recently found to form oligomers 14, 28 . To determine which factors contribute to this process, we monitored the interaction of Der1 equipped with a Myctag (Der1-Myc) and untagged Der1 in cells expressing both proteins and lacking individual components of the HRD ligase. By precipitating Der1-Myc under native conditions, we found that only the deletion of usa1 abrogated Der1 oligomerization (Fig. 1b) . Mutations in the Usa1 interaction motif also caused the dissociation of Der1 oligomers (Fig. 1c) . Importantly, Der1-Myc as well as co-expressed Der1 was stable in usa1-deleted cells, and thus a loss of oligomerization cannot be explained by Der1 instability (Supplementary Fig. 1d ). A C-terminally HA-tagged version of Der1, which is unstable in usa1-deleted cells, was also associated with co-expressed Der1 in a Usa1-dependent manner ( Supplementary Fig. 1e ). However, overexpression of Der1, by inducing a cellular stress response pathway termed the unfolded protein response (UPR) by dithiothreitol treatment 29, 30 , partially bypassed the requirement of Usa1 for oligomerization (Fig. 1d) . Therefore, Der1, similarly to Hrd1 (ref. 20) , exhibits an intrinsic propensity to form oligomers. Under unstressed growth conditions, however, efficient oligomerization of both proteins relies on their assembly by Usa1.
Mutation of conserved residues in the transmembrane domains of Der1 blocks the dislocation of CPY *
Der1 is predominantly involved in the turnover of misfolded ERluminal proteins but it is unknown how it contributes to this process 16, 17 . As Der1 binds client proteins even in the absence of the substrate receptor Hrd3, it was proposed that it constitutes a substrate recruitment factor of the HRD ligase 12, 20, 31 . However, the deletion of der1 already phenocopied the defect in the turnover of CPY * , a well established ER-luminal ERAD substrate, observed in hrd3-or hrd1-deleted cells and the combined deletion of der1 and hrd3 did not enhance this effect (Fig. 2a) . In der1-and yos9-deleted cells, we obtained a similar result (Fig. 2b) . Moreover, the absence of Der1 could not be compensated by the simultaneous overexpression of Hrd1 and Hrd3 ( Supplementary  Fig. 2a) . Immunoprecipitation experiments revealed that the amount of CPY * associated with the HRD ligase was strongly reduced in the absence of Hrd3, whereas it remained largely unchanged in der1-deleted cells (Fig. 2c, lane 11 and lane 10) . Overall, these observations suggest a function of Der1 in line with rather than parallel to Hrd3/Yos9.
On the basis of sequence similarity to rhomboid proteases, ref. 32 proposed six transmembrane segments for the mammalian homologue HA-tagged Hrd1 was immunoprecipitated with anti-HA antibodies and the bound proteins were analysed by SDS-PAGE and immunoblotting. (d) Graphical presentation of three independent experiments monitoring CPY * degradation in the indicated Der1 mutant strains by pulse chase analysis as in a. (e) CPY * -Myc was immunoprecipitated from total cell lysates with anti-Myc antibodies. The precipitates were analysed by SDS-PAGE and immunoblotting using anti-ubiquitin antibodies. rpt4R refers to a yeast strain expressing a dysfunctional version of the proteasomal AAA-ATPase Rpt4, which causes the accumulation of ubiquitylated proteins. The asterisk denotes unspecific reactivity with the heavy chains of the antibody used in the immunoprecipitation. (f) Protease-protection assay to monitor the export of CPY * from the ER. Cells of the indicated genotypes were incubated with cycloheximide (CHX) for 1 h and lysed under conditions that allowed the formation of vesicles (Methods). The samples were treated with proteinase K and Triton X-100 or left untreated. Proteins were precipitated and analysed by SDS-PAGE. Immunoblotting with anti-Kar2 antibodies serves as a control for the integrity of the vesicles. The processing of the ER luminal protein Kar2 to a protease-resistant fragment (*) in the absence of Triton X-100 indicates a leakage of some vesicles. Uncropped images of blots/gels are shown in Supplementary Fig. 6 .
derlin-1. In contrast, predictions based on hydrophobicity analysis as well as detailed biochemical studies support a topology of Der1 that comprises only four transmembrane domains 16 . Nonetheless, the position of the transmembrane domains one and two is essentially the same in both models. We investigated whether these segments are solely required for proper integration of Der1 into the HRD ligase or whether they constitute a distinct functional entity for ERAD. Sequence alignment of yeast Der1 and its homologues from different organisms revealed conserved hydrophilic amino acids particularly in the first and second transmembrane domains (Supplementary Fig. 1a ). We changed some of these residues to alanine or leucine and monitored the effects on ERAD (Supplementary Table 1 ). Mutations in the first transmembrane segment (R17L and C23L; Der1RC) moderately affected the turnover of the prevalent ERAD substrate CPY * (Fig. 2d) . A stronger defect was observed for the exchange of a conserved asparagine residue (N73L; Der1N) in the second transmembrane domain. The combination of R17L with N73L (Der1RN) caused a severe delay in CPY * degradation. Notably, these mutations also stalled the turnover of PrA*, another well-established soluble luminal ERAD substrate, whereas the degradation of 6xMyc-Hmg2, which relies on the HRD ligase but does not require Der1 (ref. 33) , proceeded at similar rates in wild-type and Der1 mutant cells (Supplementary Fig. 2b ). Mutations in the first luminal loop or in other regions of Der1 did not derogate ERAD (Supplementary Table 1 ). Der1N, Der1RN and Der1RC are stably expressed at levels comparable to the wild-type protein ( Supplementary  Fig. 2c ). Moreover, as determined by immunoprecipitation, the ability to form oligomers and the association with components of the HRD ligase were not affected ( Supplementary Fig. 2d,e) .
In cells deleted for der1 or expressing Der1RN, we were unable to detect significant amounts of ubiquitylated CPY * (CPY * -Myc-Ub; Fig. 2e , lanes 10, 12). As protein ubiquitylation is exclusively catalysed in the cytoplasm, the export of substrates from the ER seemed to be disturbed. Indeed, we found that most CPY * was protected from proteinase K treatment in lysates of these cells, indicative of localization within a membrane-bound compartment (Fig. 2f) . In contrast, Der1RC cells contained low amounts of ubiquitylated CPY * and exhibited a partial sensitivity of CPY * to proteinase K corresponding to the milder degradation defect in this mutant (Fig. 2e, lane 11; Fig. 2f ).
Spatial proximity of Der1 to components of the HRD ligase
To get further insights into the function of the Der1 transmembrane domains, we employed an in vivo site-specific photocrosslinking approach 34, 35 . Der1-Myc was labelled in living cells with the photoreactive amino acid analogue p-benzoylphenylalanine (pBpa) by overexpressing plasmid-encoded constructs that harbour a single amber stop codon at defined positions. The expression of a suppressor transfer RNA charged with pBpa allowed the incorporation of this crosslinker at the specified locations. On irradiation of cells with ultraviolet light pBpa was activated and crosslinked to neighbouring proteins. Der1-Myc was then precipitated with anti-Myc antibodies from cell lysates and the samples were analysed by immunoblotting. We focused our studies on positions in the transmembrane domains as well as the first luminal loop of Der1 because these parts seemed to be most conserved. Notably, the overexpression of Der1 does not significantly interfere with the degradation of luminal substrates ( Supplementary  Fig. 3c ) 14, 20 . Furthermore, we conducted most of these experiments in cells expressing a catalytically inactive variant of the ERAD-specific ubiquitin-conjugating enzyme Ubc7 (Ubc7C/S) to abrogate ERAD and thereby adjust the cellular levels of substrate molecules.
We found prominent crosslinking products with Hrd1 at several positions in the amino-terminal part of the first and less intense crosslinks at a few positions in the second transmembrane region of Der1 ( Fig. 3 (Fig. 4a) . Crosslinks to Usa1 were almost exclusively observed for positions in the region around amino acids 146-152, which is consistent with the notion that the downstream part of Der1 is required for the binding to Usa1 ( Fig. 3 ; positions Ile 146, Val 148, Pro 150 and Ile 152). Surprisingly, we also detected major crosslinks to the putative substrate receptor Hrd3 predominantly for residues in the first ER-luminal loop of Der1 ( Fig. 3 ; positions Gly 38, Leu 46, Lys 50 and Gln 52) whereas reactions to the Hrd3-associated lectin Yos9 were not found ( Supplementary  Fig. 3a) . Again, the crosslinking reactions depended on the recruitment of Der1 to the HRD ligase through Usa1 (Fig. 4b) . A functional variant of Hrd3 that is deleted for the transmembrane region and comprises only the luminal domain (Hrd3 1-769 ; ref. 12) also formed crosslinks with the pBpa-labelled Der1 variants, demonstrating a close spatial proximity between the luminal parts of both proteins (Fig. 4c) . Some of the Der1-Hrd3 crosslinks involved residues that were calculated to map to the integral membrane domains of Der1 ( Fig. 3 ; positions Arg 33 and Asp 62). Given that the predicted position of the transmembrane segments is correct, this indicated that the Hrd3 luminal domain is capable to immerge into the membraneembedded part of Der1. By co-expressing pBpa-labelled Der1-Myc and unlabelled Der1-HA, we detected crosslinking products of these proteins primarily for positions in the transmembrane regions (Fig. 4d ). This finding confirms oligomer-formation of Der1 as suggested by the immunoprecipitation experiments and implies a tight association of the membrane-embedded segments within this assembly.
Strikingly, pBpa-labelled Der1 could also be crosslinked to the ERAD substrate CPY * -HA. The most prominent crosslinks involved the luminal loop one and the luminally orientated parts of the Der1 transmembrane segments one, two and four ( Fig. 3 and Supplementary  Fig. 3b , for example, positions Arg 33, Gly 38, Lys 50, Ile 60, Asp 62 and Ile 146). Position Gly 38, which maps to the first ER-luminal loop of Der1, was of special interest because this residue seemed to be localized in close proximity to the substrate as well as to the substrate receptor Hrd3. Unlabelled Der1-Myc did not form crosslinks with CPY * -HA or components of the HRD ligase ( Fig. 3 ; leftmost lanes). Moreover, no crosslinks were detected when the ultraviolet treatment was omitted. The modification of Der1 with pBpa did not affect the stability of the protein and had no significant effect on the activity of Der1 ( Supplementary Fig. 3c ). Furthermore, pBpa-labelled Der1 variants were properly assembled into the HRD ligase as determined by the immunoprecipitation of selected constructs ( Supplementary  Fig. 3d ). These results identified Der1 as a central factor in the HRD ligase protein complex and implied that ER-luminal as well as membrane-embedded regions of Der1 reside in close contact to a soluble degradation substrate.
Der1 directly binds substrate molecules
Previous work indicated that Der1 exhibits a weak but specific substrate-binding activity 12 . We therefore investigated the impact of the substrate receptor Hrd3 on the Der1-CPY * crosslinks. To level out cellular protein amounts of CPY * -HA, we conducted these experiments in Ubc7C/S cells (see above). The amount of CPY * that crosslinked to specific positions in the luminal loop of Der1 was substantially increased in the hrd3-deleted strain, which correlates to previous studies 31 ( Fig. 5a ). Likewise, the release of Der1 from the HRD ligase in cells lacking Usa1 mildly affected substrate crosslinking Der1-Myc (Anti-Myc) at positions in the luminal loop ( Supplementary Fig. 4a ). Notably, owing to the overexpression of Der1 in the crosslinking set-up, the oligomeric state of the protein is still intact despite the deletion of usa1 ( Supplementary Fig. 4b , compare lanes 5 and 6). Consistently, substrate binding to Der1-Myc or Der1-HA depended neither on Usa1 nor on Hrd3 as determined by immunoprecipitation in Ubc7C/S cells (Fig. 5b , compare lanes 6, 7 and 8; Supplementary Fig. 4c , compare lanes 5 and 6). To substantiate the specificity of the Der1-CPY * crosslinks, we compared wild-type and ubiquitylation-deficient Ubc7C/S cells in the crosslinking experiments. The overall crosslinking pattern to Hrd1, Usa1 or Hrd3, which form a stable complex with Der1, was not affected by the activity of the ligase ( Fig. 5c and Supplementary  Fig. 4d ,e). However, the amount of crosslinking products was increased in Ubc7C/S cells, possibly owing to upregulation of the HRD ligase components by the UPR (ref. 30 and Supplementary Fig. 4f ). In wild-type cells, the amount of crosslinked CPY * -HA was clearly reduced, albeit the relative intensity was almost identical for selected Der1 positions. This observation matched the idea that in the course of substrate processing, no prevalent degradation intermediate of CPY * -HA accumulated at Der1. Intriguingly, this pattern was changed in the Ubc7C/S cells, indicating that substrate molecules arrested in a particular constitution at the HRD ligase (Fig. 5c) . We also observed crosslinks of the ERAD substrate PrA*-HA to defined positions of Der1. The pattern of these crosslinks correlated with those observed for CPY * -HA, suggesting that both substrates arrested in the same fashion at Der1 (Fig. 5d) .
Importantly, pBpa-Der1-Myc could not be crosslinked to properly folded CPY-HA (Fig. 5e ) or stable ER resident proteins such as Kar2, an Hsp70-type ER-luminal chaperone 36 , or Sec61, a membrane-bound component of the protein import apparatus 37 ( Supplementary Fig. 4g ), demonstrating that only proteins that are targeted for degradation by the HRD ligase come into spatial proximity to Der1.
Mutations in the Der1 transmembrane domains affect the crosslinking to HRD ligase components and CPY
* -3xHA In the following, we employed the ERAD-deficient Der1RN mutant in the crosslinking experiments. Although this mutant protein seemed to be properly integrated into the HRD ligase as determined by immunoprecipitation, the amount of most crosslinking products with Hrd1, Usa1 and Hrd3 was significantly reduced, indicating moderate structural changes in Der1 (Fig. 6a,b and Supplementary Fig. 5a ). In contrast, the crosslinking products with CPY * -HA were increased predominantly at positions in the luminal loop of Der1 (Fig. 6a,b , right panel, compare lanes 5 and 7). It is noteworthy that the cellular level of this substrate remained unchanged ( Supplementary Fig. 5b) . Moreover, the individual pBpa-labelled Der1 variants precipitated equal amounts of CPY * -HA, indicating that their ability to bind substrate molecules was not affected (Supplementary Fig. 5b ). This strongly implied that ERAD substrates were unable to enter a dislocation complex in Der1RN cells, which in turn caused their accumulation at the luminal-exposed parts. Importantly, the crosslinking pattern of Der1 and Der1RN to CPY * -HA was almost identical on the release of these proteins from the HRD ligase in cells deleted for usa1 (Fig. 6c , compare lanes 5 and 7 with Fig. 6a, lanes 5 and 7) . Thus, the accumulation of a particular degradation intermediate of CPY
* -HA depended on the correct integration of Der1 into the HRD ligase.
DISCUSSION
Before their degradation, misfolded proteins of the secretory pathway are routed from the ER into the cytoplasm. Intriguingly, these proteins are often modified by complex glycans, contain disulphide bridges and may be partially folded. This poses special requirements for the movement of such polypeptides through the ER membrane. Previous work indicated that mammalian derlin-1, a homologue of Der1, is involved in this process 38, 39 . When overexpressed in mammalian cells, derlin-1 and also the closely related derlin-2 and -3 proteins were shown to form oligomers, which are associated with ERAD ligases [40] [41] [42] . Moreover, a protein complex containing derlin-1 bound to client proteins before and after their extraction from the ER (ref. 38) . Concordantly, the release of a model substrate from microsomes in a reconstituted system was efficiently inhibited by the addition of derlin-1-specific antibodies 43 . Although similar in size and topology, Der1 and the derlin proteins exhibit functional differences. The derlins share certain amino acid motifs with inactive rhomboid proteases and contain a so-called SHP-box motif in their cytoplasmic C-terminal domain for direct binding to the AAA-ATPase p97, which are less conserved or not present in Der1  (ref. 32) . Moreover, the mammalian derlin proteins are involved in the turnover of soluble and membrane-bound proteins, whereas Der1 is almost exclusively required for the degradation of soluble, ER-luminal substrates 38, 44, 45 .
Our data now provide strong evidence that yeast Der1 directly partakes in the extraction of aberrant proteins from the ER lumen. First, on Usa1-dependent assembly into the HRD ligase, Der1 forms 
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Anti Figure 6 Dislocation-deficient point mutants of Der1 affect the crosslinking to HRD ligase components and CPY * -HA. (a) der1 Ubc7C/S CPY * -HA cells were transformed with high-copy plasmids encoding either Der1-Myc (derived from pMM075) or Der1RN-Myc (derived from pMM074) that contain photoreactive probes in the first (Ser 31) and fourth (Ile 146) transmembrane domain or in the first luminal loop (Gly 38). On ultraviolet irradiation and cell lysis, the Der1-Myc variants were subjected to immunoprecipitation with anti-Myc antibodies. The crosslinked interaction partners were analysed by SDS-PAGE and immunoblotting using specific antibodies. (b) Positions that show significant crosslinks with Hrd1 (left panel) or Hrd3 (right panel) were modified with pBpa in Der1-Myc and Der1RN-Myc, respectively. The Der1 constructs were expressed in der1 Ubc7C/S CPY * -HA cells and pBpa was activated by ultraviolet light. (c) The same as in a, but the Der1-Myc variants were expressed in der1 Ubc7C/S CPY * -HA cells that were deleted for usa1. Uncropped images of blots/gels are shown in Supplementary Fig. 6 . oligomers in the ER membrane, which may be a prerequisite to enable the transit of substrate proteins across a lipid layer. Second, the exchange of conserved polar residues in the transmembrane domains of Der1 abolishes export of polypeptides from the ER without affecting the overall topology of the HRD ligase. Third, client proteins form crosslinks to ER-luminal as well as membrane-embedded parts of Der1, indicating that they are in close proximity to Der1 during dislocation from the ER. We are aware that the in vivo crosslinking approach allows the unspecific incorporation of pBpa into proteins that are naturally terminated by an amber stop codon, which causes the production of abnormal species with C-terminal extensions. Still, we did not observe physiological alterations in pBpa-labelled cells and were unable to detect crosslinking products to unlabelled Der1-Myc. Fourth, the efficiency of pBpa-Der1 crosslinking to substrate molecules depends on the activity of the ligase and the assembly of Der1 into the ligase complex. Fifth, Der1 is located in the immediate vicinity of the substrate receptor Hrd3 as well as the ubiquitin ligase Hrd1 and is therefore at a prominent position to functionally link substrate selection in the ER lumen with the ubiquitylating activity at the cytoplasmic face of the ER. On the basis of these observations, we propose the following model for Der1 activity (Fig. 7) . Malfolded proteins engage Hrd3 and Yos9 where they are selected for degradation. Those receptors then pass substrates to Der1, which acts downstream. Der1 contains regions in the ER lumen that are in close proximity to Hrd3 and weakly bind aberrant polypeptides. This activity does not bypass the requirement for Hrd3 and Yos9 in ERAD. Rather, the access to Der1 seems to be restricted to client molecules that were pre-selected by Hrd3/Yos9. In the absence of Hrd3, Der1 probably binds polypeptides with low affinity, which does not suffice to trigger their degradation. Interestingly, mutations in the ER-luminal part of mammalian derlin-1 abolished its function in ERAD (ref. 32). We did not observe a similar effect for the corresponding positions in Der1, but we did not systematically investigate this issue. Next, Der1 initiates the insertion of substrate molecules into the ER membrane. The assembly of multiple Der1 subunits may generate a flexible funnel that supports immersion of even folded client proteins. Importantly, this step guides the substrates in spatial proximity to Hrd1 and arranges them for ubiquitylation. The subsequent movement through the membrane may involve a proteinaceous pore that contains Der1 and other proteins. Recently, the ubiquitin ligase Hrd1 has been implicated in the formation of such a conduit 14, 20 . Hrd1 contains six transmembrane segments and also forms oligomers. Whereas a mild 5-10-fold overexpression of Hrd1 failed to compensate for a loss of Der1 ( Supplementary Fig. 2a Moreover, arrested dislocation intermediates could be crosslinked to Hrd1, which depended on the catalytic activity of the HRD ligase 20 . In contrast, crosslinks of substrates with Der1 were increased in a ubiquitylation deficient mutant. As ubiquitylation was found to be mandatory for protein extraction from the ER, this modification most likely prevents the dissociation of client proteins from Hrd1 and drives their export by the ubiquitin-dependent AAA-ATPase Cdc48/p97 (ref. 46) . Still, mutations in the Hrd1 transmembrane segments, which blocked the degradation of membrane-bound targets, had no impact on the turnover of soluble client proteins 47 . Hence, further studies are needed to elucidate the detailed composition of the conduit that channels soluble ERAD substrates through the ER membrane.
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M E T H O D S METHODS
Antibodies.
Monoclonal anti-HA (H9658, Sigma-Aldrich; C29F4, NEB) and anti-Myc (M5546, Sigma-Aldrich) antibodies used for immunoprecipitation (dilution 1:2,000) and detection (dilution 1:2,500-1:5,000) were commercially available. Antibodies for immunodetection of Hrd1 (1:10,000), Hrd3 (1:3,000), Sec61 (1:10,000), Der1 (1:500) and Usa1 (1:3,000) were described previously 12, 14 . Antibodies for immunodetection of Kar2 (1:10,000) and Pep4 (1:3,000) were a generous gift from T. A. Rapoport and D. H. Wolf, respectively. The monoclonal antibody directed against CPY (A-6428; used at 1:2,500 for immunoprecipitation and 1:5,000 for immunodetection) was purchased from Molecular Probes. Fluorescently labelled secondary antibodies (IRDye 800, anti-mouse IgG (goat) and IRDye 800, anti-rabbit (goat); each used at 1:2,000 for immunodetection using a Li-Cor system) were purchased from Rockland. The polyclonal anti-Yos9 antibody was generated by immunizing rabbits with a fragment of Yos9 purified from Escherichia coli and used at a dilution of 1:2,000 for immunodetection. The polyubiquitin-specific antibody (UG9510, Enzo Life Science) was diluted 1:2,000 for immunoblotting. Horseradish-peroxidase-coupled secondary antibodies (A9044 and A0545; both diluted 1:10,000) used for immunodetection of proteins by enhanced chemiluminiscence were purchased from Sigma-Aldrich.
Yeast strains and plasmids. For yeast sporulation, tetrad dissection and the preparation of yeast media, standard protocols were used 48 . The genotypes of the yeast strains are listed in Supplementary Table 2. These strains are derived from the diploid wild-type strain DF5. Described methods were followed for the deletion and chromosomal epitope tagging of genes in yeast 49, 50 . The DNA plasmids used in this study are summarized in Supplementary Table 3 . Briefly, a DNA fragment was PCR-amplified with oligonucleotides that are flanked by suitable restriction sites and inserted into appropriate vectors. The modification of plasmid-encoded genes with epitopes (pMM074, pMM075 and pMM076) was done by expressing these constructs in the respective deletion strains and homologous recombination of an appropriate DNA-cassette as described previously 50 . Der1 constructs containing point mutations were generated by QuikChange sitedirected mutagenesis using Pfu Ultra High Fidelity DNA-polymerase according to the manufacturer's instructions (Agilent Technologies). For the generation of constructs that express p-benzoylphenylalanine (pBpa)-labelled Der1 variants pMM074, pMM075 and pMM063 were used as parental plasmids. The stop codon TAG was introduced at individual positions by site-directed mutagenesis as described above. pMM001, pMM040 and pMM041 were used for the insertion of point mutations into the chromosomal locus of Der1 leading to YMM156, YMM111 and YMM112. 6xMyc-Hmg2 was expressed from plasmid pRH244 as described elsewhere 33 . pJU293 and pJU294 are 2 µm-based multicopy plasmids that contain combinations of the genes HRD1, HRD3 and DER1 under the control of their respective promoters (around 400 base pairs of the 5 non-coding sequence). Native immunoprecipitation. About 1.5 × 10 9 yeast cells in early logarithmic phase were collected and lysed by vigorous shaking with glass beads in ice-cold lysis buffer (50 mM Tris-HCl (pH 7.5), 400 mM KOAc, 0.5 mM EDTA, 10% (v/v) glycerol and 1 mM phenylmethylsulphonyl fluoride (PMSF)). The cell debris was removed by low-speed centrifugation (2,000g , 3 min). The supernatant was supplemented with 1% (w/v) digitonin (Calbiochem) and incubated for 1 h under rotation at 4 • C. The lysate was cleared by high-speed centrifugation at 20,800g for 20 min and diluted with lysis buffer to a final concentration of 0.5% (w/v) digitonin. For immunoprecipitation, specific antibodies and protein A-conjugated Sepharose were added. Bound proteins were eluted with dithiothreitol (DTT)-containing sample buffer and analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. For the immunoprecipitation of CPY * , the protocol was modified. About 4.5 × 10 9 yeast cells were collected and lysed in IP32-buffer (50 mM HEPES (pH 7.5), 50 mM NaCl, 125 mM KOAc, 2 mM MgOAc 2 , 1 mM EDTA, 10 µMCaCl 2 and 3% (v/v) glycerol). Next, microsomes were collected by high-speed centrifugation (20,800g , 20 min) and solubilized with 0.5% (v/v) Nonidet P40. The following steps were performed as described above.
Determination of protein degradation. The turnover of proteins was analysed either by pulse chase experiments or cycloheximide decay assays as described elsewhere [51] [52] [53] . Briefly, for pulse chase analysis, yeast cells were pulsed with radiolabelled 35 S methionine followed by a chase with an excess of unlabelled amino acids. During the chase, samples were taken at indicated time points and mixed with NaN 3 . The cells were lysed under denaturing conditions and the protein of interest was immunoprecipitated with specific antibodies. For the analysis of CPY * or PrA*, the bound proteins were treated with endoglycosidase F. The samples were then separated by SDS-PAGE followed by autoradiography using a PhosphoImager (Typhoon FLA9500, GE Healthcare).
For a cycloheximide decay assay, yeast cells were incubated with 0.3 mg ml −1 cycloheximide to stop protein synthesis. Samples were collected at the indicated time points and the cells were lysed with glass beads in buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM EDTA and 1 mM PMSF. Microsomes were recovered by high-speed centrifugation (20,800g , 20 min) and suspended in sample buffer. The analysis of the samples was carried out by SDS-PAGE and immunoblotting.
Detection of ubiquitylated CPY * . About 4.5 × 10 9 yeast cells were collected and washed with 20 mM N -ethylmaleimide (NEM), 10 mM NaN 3 and 1 mM PMSF. After lysis of the cells with glass beads in Ub-buffer (0.7 M sorbitol, 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100 and 0.1% (w/v) SDS) supplemented with 20 mM NEM and 1 mM PMSF, the cell extract was incubated for 1 h for efficient solubilization of membranes. Insoluble material was then cleared from the lysate (20,800g , 20 min) . Subsequently, CPY * -Myc was precipitated with anti-Myc antibodies. Bound proteins were eluted by DTT-containing sample buffer and analysed by SDS-PAGE and immunoblotting. Ubiquitylated CPY * -Myc was detected by specific anti-ubiquitin antibodies.
Site-specific in vivo photocrosslinking. Yeast cells were transformed with pGK1-pBpa (a gift from P. G. Schultz) and Der1-Myc constructs derived from pMM074 or pMM075 containing an amber stop codon at specific positions 34, 35 . Transformed yeast cells were grown in synthetic minimal medium supplemented with 400 µM pBpa (Bachem, CH) overnight at 30 • C. The expression of Der1-Myc was induced by the addition of 0.1 mM CuSO 4 for 2 h. About 4.5 × 10 9 yeast cells were collected and washed twice with ice-cold H 2 O. Next, the cells were suspended in 2 ml H 2 O, transferred to a 6-well plate and irradiated with ultraviolet light (B-100AP, UVP, CA) at λ = 365 nm for 45 min on ice. The cells were lysed with glass beads in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS and 1 mM PMSF. The lysate was cleared from cell debris and the microsomes were solubilized as described above. Insoluble material was removed by high-speed centrifugation (20,800g , 20 min) and Der1-Myc was immunoprecipitated with anti-Myc antibodies. Bound proteins were eluted with DTT-containing sample buffer and analysed by SDS-PAGE and immunoblotting. For quantification of the crosslinking efficiency, immunoblots were incubated with fluorescently labelled secondary antibodies and analysed by the Odyssey near-infrared Imaging System (Li-Cor).
Protease protection assay. To monitor the dislocation of a CPY fraction from the ER over a time period of 1 h, the protein synthesis in yeast cells was inhibited by the addition of cycloheximide as described before. Samples were collected at the indicated time points and washed with 10 mM NaN 3 . To keep the membranes intact, the cells were lysed in sorbitol buffer (0.7 M sorbitol and 50 mM Tris-HCl (pH 7.5)). Afterwards, the lysate was cleared from cell debris and treated with 0.1 mg ml −1 proteinase K, or proteinase K in the presence of 0.5% (v/v) Triton X 100 for 20 min on ice. The reaction was stopped by the addition of 1 mM PMSF and 15% (w/v) trichloro-acetic acid. The proteins were then recovered by high-speed centrifugation (20,800g , 20 min) and dissolved in sample buffer (pH 8) before analysis by SDS-PAGE and immunoblotting.
β-galactosidase activity assay. For the measurement of UPR induction, yeast cells were transformed with a UPR-induced reporter construct (pUPRE-lacZ). The β-galactosidase activity was determined as previously described 29 .
Reproducibility of experiments. All data are representative of at least three independent experiments with the exception of Fig. 1c (two independent experiments) , Supplementary Figs 1c,e, 2b right panel, 2c, 3a,c, 4c and 5a (two independent experiments each) and Supplementary Fig. 3b (one experiment). Uncropped images of key experiments can be seen in Supplementary Fig. 6 . IAVGHIYYFLEDVFPNQPGGKRLLQTPGFLGLQSSKAPAGSSLT
Derlin-1_hs GGRHNWGQGFRLGDQ 251 Derlin-1_ce GHQWPGGVGARLGGN 245 Derlin-3_hs GPGTAGELAAPS---239 16 is given by green bars. Of note, in an alternative model for Derlin-1 topology proposed by Greenblatt et al. 32 , the position of transmembrane segments one and two is almost identical. Black diamonds label amino acids in Der1, which were subjected to site-directed mutagenesis (Supplementary Table S1 ). b, Cycloheximide decay assay to monitor the degradation of Der1 in strains of the indicated genotypes. c, As in b but Dder1 cells were transformed with low-copy number plasmids encoding mutants of Der1. d, Cycloheximide decay decay assay to determine turnover of Der1-Myc and Der1 in Dusa1 cells. The integral ER-membrane protein Sec61 served as loading control. e, Plasmid-encoded HA-tagged Der1 was expressed with endogenous Der1 in cells containing or lacking Usa1. Membranes of the total extract were solubilised with Digitonin and Der1-HA was precipitated with anti-HA antibodies followed by SDS-PAGE and immunoblotting. Figure 4 Der1 is in close proximity to dislocated CPY*. a, Photoreactive probes were placed at the indicated positions in Der1-Myc. The constructs were expressed in Dder1 Ubc7C/S CPY*-HA cells either containing or lacking Usa1 and exposed to UV light. The samples were then lysed and subjected to immunoprecipitation as described in Figure 3 . b, Der1-HA expressed from high-copy plasmid pMM079 was transformed into Dder1 Ubc7C/S cells either containing or lacking Usa1. Der1-Myc labelled with pBpa at position G38 (derived from pMM075) was co-expressed where indicated. Cells were lysed in Digitonin containing buffer and Der1-Myc was immunoprecipitated with anti-Myc antibodies. Interacting Der1-HA was detected by immunoblotting. c, Dder1 Ubc7C/S cells were transformed with a low-copy plasmid encoding Der1-HA. Microsomes of these cells were solubilised with NP40 and Der1-HA was precipitated with anti-HA antibodies. The catalytically inactive Ubc7 mutant (Ubc7C/S) was used to adjust the substrate levels in the individual strains. d, Der1-Myc constructs with photoreactive probes placed at positions which reveal prominent crosslinks with Hrd1 were expressed either in Dder1 CPY*-HA cells (wt) or in Dder1 CPY*-HA Ubc7C/S cells. The photocrosslinking was performed as described. e, As in d but the Der1-Myc constructs contained photoreactive probes at positions, which formed crosslinks with Usa1. f, Determination of the unfolded protein response (UPR) in strains used for the crosslinking experiments by ß-galactosidase activity assay. The indicated yeast strains were transformed with the pUPRE-lacZ plasmid and the activity of ß-galactosidase was measured as described (see Methods). Where indicated cells were treated with 4 mM Dithiotriol (DTT) for 1 hour before ß-galactosidase measurement to fully induce the UPR. Error bars and mean values of three independent experiments are shown. g, Der1-Myc variants labelled at the indicated positions were expressed in Δpep4 Ubc7C/S cells containing plasmid-encoded PrA*-HA. The crosslinking experiment was performed as in a. Figure 5 The pBpa-labelled Der1RN-Myc transmembrane mutant is properly assembled with the HRD-ligase but displays alterations in the crosslinking to its interaction partners. a, Dder1 Ubc7C/S CPY*-HA cells were transformed with high-copy plasmids encoding either pBpamodified Der1-Myc (derived from pMM075), Der1RN-Myc (derived from pMM074) or unlabelled Der1-Myc (pMM075). Digitonin-solubilised membranes of the total extract were subjected to immunoprecipitation with anti-Myc antibodies (left and right panel). b, As in a but the microsomes were solubilised with NP40 before precipitation of the Der1-Myc constructs. 
